SR9009
Also known as: Stenabolic
preclinical onlyWADA bannedNot FDA approvedResearch only
Published Dose Range
Low10 mg/day
Typical20-30 mg/day
High40 mg/day
REV-ERB agonist (not a true SARM). Poor oral bioavailability — the compound sold to users as SR9009 likely has very limited systemic effect. Very short half-life.
Published Cycle Range
Short4 wks
Typical6 wks
Long8 wks
Short-lived effects — cycle length based on anecdote rather than data.
Off-cycle: 4 weeks
Administration
Routesoral
Frequency4-6x daily
Preferred timingSplit every 3-4 hours while awake
Half-life ~4 hours. Requires frequent dosing for any sustained effect.
Safety Profile
Contraindications
- • Pregnancy
Common side effects
- • Mild GI upset
Serious risks
- • Poor oral bioavailability makes benefit uncertain
- • Long-term safety unknown
Pregnancy / breastfeeding
Contraindicated
Common Misconceptions
- Not a SARM — REV-ERB agonist
- Oral bioavailability is the fundamental problem — most user reports may be placebo
Commonly Stacked With
GW-501516
Next Steps
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.